Skip to main content
. 2016 Nov 30;232(6):1571–1578. doi: 10.1002/jcp.25685

Figure 2.

Figure 2

Progression‐free survival (PFS, A) and overall survival (OS, B) according to administration of bevacizumab maintenance (BM) and adjusted for propensity score (PFS, C; OS, D).